Carolina Pines Regional Medical Center to begin using monoclonal antibody treatment for COVID-19 patients
Carolina Pines Regional Medical Center in Hartsville announces that it has received initial doses of Bamlanivimab, a new monoclonal antibody treatment for COVID-19. The drug was developed by pharmaceutical company Eli Lilly to help treat non-hospitalized patients with mild or moderate cases of COVID-19. The Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) allowing hospitals to begin administering the drug to patients. Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful viruses. Eli Lilly’s monoclonal antibody therapy for COVID-19 is designed to help block the SARS-CoV-2 virus and prevent the virus from further infecting healthy cells. Administered intravenously, this innovative treatment is designed to help lessen the severity of COVID-19 in individuals who are COVID-19-positive and are at risk for developing a severe form of the disease. Patients must meet specific clinical criteria, including having a lab-confirmed case of COVID-19 that is mild or moderate; having underlying health conditions or being over 65 years of age; and patients must also be stable enough not to require hospitalization. This is a limited, investigational treatment that is being carefully allocated by the Department of Health and Environmental Control and requires an order from your provider. Our providers will continue to carefully monitor patients who have received this therapy and will evaluate other COVID-19-positive individuals for whom this therapy may be effective, following strict criteria for administration. Offering this treatment is an important step forward in helping prevent the most at-risk patients from being hospitalized due to COVID-19.